<DOC>
	<DOCNO>NCT02443545</DOCNO>
	<brief_summary>This long-term follow-up earlier study , LA38-0411 . Its purpose gather information safety efficacy deferiprone patient sickle cell disease anemias suffer iron overload cause regular blood transfusion .</brief_summary>
	<brief_title>Long-term Safety Efficacy Ferriprox® Iron Overloaded Patients With Sickle Cell Disease Other Anemias</brief_title>
	<detailed_description>Deferiprone ( brand name Ferriprox® ) iron chelator approve United States 60 country treatment iron overload patient thalassemia , treatment inadequate . This study design evaluate long-term efficacy , safety , tolerability deferiprone treat iron overload patient sickle cell disease anemia . Only patient complete earlier study , LA38-0411 , eligible enroll one .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Completed study LA380411 2 . Females childbearing potential must negative pregnancy test result Visit 1 . In addition , applicable , must : Use effective method contraception accord local requirement , study within 30 day follow last dose study medication , OR Have tubal ligation ( support evidence require ) , OR Have hysterectomy ( support evidence require ) , OR Participate nonheterosexual lifestyle , OR Have male sexual partner sterilize ( support evidence require ) 3 . Fertile heterosexual male and/or partner must agree use effective method contraception study 30 day follow last dose study medication 4 . All patient and/or authorized legal representative must provide sign dated write informed consent prior first study intervention , assent obtain patient consider minor . Patients must able adhere study restriction , appointment , evaluation schedule . 1 . Plan participate another clinical trial time day enrollment 30 day posttreatment current study 2 . For patient treat deferoxamine study LA380411 ( Group 2 ) : Presence medical condition ( include clinically significant laboratory abnormality , ALT ≥ 5 x ULN creatinine ≥ 2 x ULN ) , psychological condition , psychiatric condition opinion investigator would cause participation study unwise . 3 . Pregnant , breastfeeding , plan become pregnant study period . 4 . Treatment failure 1 year deferiprone investigator 's judgment indicate need patient start different iron chelator</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Iron overload</keyword>
	<keyword>Sickle cell disease</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Ferriprox</keyword>
	<keyword>Iron chelation</keyword>
</DOC>